Shire warns ADS holders not to accept TRC Capital's 'mini-tender' offer

30 July 2016

Ireland-headquartered Shire (LSE: SHP) says it has been notified of an unsolicited “mini-tender” offer made by TRC Capital Corp to purchase up to 1 million Shire American Depositary Shares (ADSs), each representing three ordinary shares of Shire, at a price of $182.75 per ADS in cash.

The offer is for around 0.33% of the outstanding ordinary shares of Shire, and is less than the $194.12 that the ADSs were trading at on Friday.

Shire does not endorse this unsolicited mini-tender offer and recommends that ADS holders reject the offer and do not tender their ADSs in response to the offer. Shire is not associated with TRC Capital, its mini-tender offer or the mini-tender offer documentation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK